Auxly Cannabis Group (XLY) Q4 2024 earnings summary

Executive summary

• Net loss for 2024 was $16.3 million, a significant improvement from a $44.5 million loss in 2023, driven by higher revenues and lower impairment charges.

• Total net revenue increased to $122.3 million in 2024 from $101.1 million in 2023, with Q4 2024 net revenue at $34.6 million, up 29% year-over-year.

• Adjusted EBITDA reached $26.7 million in 2024, up from $1.5 million in 2023.

• Gross profit rose to $59.9 million in 2024 from $21.3 million in 2023, with gross margin on finished cannabis inventory sold at 46% for the year.

• SG&A expenses reduced by 8% for the year, reflecting operational efficiencies.

Financial highlights

• Revenue from cannabis sales grew 22% year-over-year to $185.7 million.

• Inventory impairment losses decreased to $2.3 million in 2024 from $10.5 million in 2023.

• Cash flow from operating activities was $16.8 million in 2024, up from $8.2 million in 2023; cash at year-end totaled $18.4 million.

• Total debt reduced by 56% in 2024, mainly due to conversion of $123 million debt into shares and repayment of debenture facility.

• Gross profit margin for 2024 was 49%, up from 21% in 2023.

Outlook and guidance

• Material uncertainty exists regarding the ability to continue as a going concern due to negative working capital of $46.7 million and insufficient cash to fund operations for the next 12 months without improved sales or additional financing.

• Expects further improvement in 2025 through innovation, expanded distribution, and enhanced production efficiency.

• Management is prioritizing higher-return products, cost reductions, and may seek further debt or equity financing and asset sales.

• Focus remains on operational discipline, cost control, and profitable growth.

• Intends to continue reducing debt and cost of capital while maintaining liquidity.